Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Buy
56
CTMX Quote, Financials, Valuation and Earnings
Last price:
$5.44
Seasonality move
:
12.07%
Day range:
$5.33 - $5.56
52-week range:
$0.40 - $6.35
Dividend yield:
0%
P/E ratio:
12.98x
P/S ratio:
5.51x
P/B ratio:
8.57x
Volume:
1.9M
Avg. volume:
3.5M
1-year change:
565.36%
Market cap:
$920M
Revenue:
$138.1M
EPS (TTM):
$0.42
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CTMX
CytomX Therapeutics, Inc.
|
$7.3M | -$0.09 | -87.67% | -23% | $9.00 |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$292.5M | $0.14 | 13.44% | 28.72% | $31.21 |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$1.2B | $1.50 | 89.86% | -58.59% | $457.00 |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$835M | $0.56 | 11.9% | 36.21% | $88.87 |
|
RGNX
REGENXBIO, Inc.
|
$75.6M | -$0.44 | -22.97% | -18.77% | $29.18 |
|
SVRA
Savara, Inc.
|
-- | -$0.12 | -- | -2.6% | $10.81 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CTMX
CytomX Therapeutics, Inc.
|
$5.43 | $9.00 | $920M | 12.98x | $0.00 | 0% | 5.51x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$23.99 | $31.21 | $4.1B | 15.44x | $0.00 | 0% | 3.86x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$336.19 | $457.00 | $44.6B | 148.95x | $0.00 | 0% | 12.08x |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$64.08 | $88.87 | $12.3B | 24.01x | $0.00 | 0% | 4.06x |
|
RGNX
REGENXBIO, Inc.
|
$8.14 | $29.18 | $412.1M | -- | $0.00 | 0% | 2.58x |
|
SVRA
Savara, Inc.
|
$5.53 | $10.81 | $1.1B | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CTMX
CytomX Therapeutics, Inc.
|
4.95% | 12.893 | 1.06% | 3.54x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
5.64% | 2.900 | 1.52% | 2.70x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
79% | 1.064 | 5.64% | 2.51x |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
9.17% | -0.896 | 5.87% | 2.84x |
|
RGNX
REGENXBIO, Inc.
|
62.42% | -0.981 | 54.89% | 2.40x |
|
SVRA
Savara, Inc.
|
24.02% | -1.971 | 4.83% | 7.42x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CTMX
CytomX Therapeutics, Inc.
|
$5.8M | -$15.9M | 52.07% | 61.33% | -266.11% | -$15.4M |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$257M | $35.8M | 31.98% | 34.23% | 12.83% | $73.9M |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$829.3M | $131.7M | 10.18% | 107.73% | 12.01% | $140.3M |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$641.8M | $184.9M | 8.12% | 8.99% | 23.5% | $334.9M |
|
RGNX
REGENXBIO, Inc.
|
$20.1M | -$52.4M | -40.97% | -73.5% | -176.27% | -$56.5M |
|
SVRA
Savara, Inc.
|
-$76K | -$30.3M | -65.99% | -78.83% | -- | -$22.5M |
CytomX Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns CTMX or ACAD?
ACADIA Pharmaceuticals, Inc. has a net margin of -238.62% compared to CytomX Therapeutics, Inc.'s net margin of 25.76%. CytomX Therapeutics, Inc.'s return on equity of 61.33% beat ACADIA Pharmaceuticals, Inc.'s return on equity of 34.23%.
Company Gross Margin Earnings Per Share Invested Capital CTMXCytomX Therapeutics, Inc.97.75% -$0.09 $113M ACADACADIA Pharmaceuticals, Inc.92.23% $0.42 $972.1M -
What do Analysts Say About CTMX or ACAD?
CytomX Therapeutics, Inc. has a consensus price target of $9.00, signalling upside risk potential of 65.75%. On the other hand ACADIA Pharmaceuticals, Inc. has an analysts' consensus of $31.21 which suggests that it could grow by 30.1%. Given that CytomX Therapeutics, Inc. has higher upside potential than ACADIA Pharmaceuticals, Inc., analysts believe CytomX Therapeutics, Inc. is more attractive than ACADIA Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CTMXCytomX Therapeutics, Inc.5 2 0 ACADACADIA Pharmaceuticals, Inc.9 6 1 -
Is CTMX or ACAD More Risky?
CytomX Therapeutics, Inc. has a beta of 2.444, which suggesting that the stock is 144.417% more volatile than S&P 500. In comparison ACADIA Pharmaceuticals, Inc. has a beta of 0.660, suggesting its less volatile than the S&P 500 by 33.951%.
-
Which is a Better Dividend Stock CTMX or ACAD?
CytomX Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ACADIA Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CytomX Therapeutics, Inc. pays -- of its earnings as a dividend. ACADIA Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CTMX or ACAD?
CytomX Therapeutics, Inc. quarterly revenues are $6M, which are smaller than ACADIA Pharmaceuticals, Inc. quarterly revenues of $278.6M. CytomX Therapeutics, Inc.'s net income of -$14.2M is lower than ACADIA Pharmaceuticals, Inc.'s net income of $71.8M. Notably, CytomX Therapeutics, Inc.'s price-to-earnings ratio is 12.98x while ACADIA Pharmaceuticals, Inc.'s PE ratio is 15.44x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CytomX Therapeutics, Inc. is 5.51x versus 3.86x for ACADIA Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CTMXCytomX Therapeutics, Inc.5.51x 12.98x $6M -$14.2M ACADACADIA Pharmaceuticals, Inc.3.86x 15.44x $278.6M $71.8M
-
Which has Higher Returns CTMX or ALNY?
Alnylam Pharmaceuticals, Inc. has a net margin of -238.62% compared to CytomX Therapeutics, Inc.'s net margin of 16.99%. CytomX Therapeutics, Inc.'s return on equity of 61.33% beat Alnylam Pharmaceuticals, Inc.'s return on equity of 107.73%.
Company Gross Margin Earnings Per Share Invested Capital CTMXCytomX Therapeutics, Inc.97.75% -$0.09 $113M ALNYAlnylam Pharmaceuticals, Inc.75.6% $1.37 $3.8B -
What do Analysts Say About CTMX or ALNY?
CytomX Therapeutics, Inc. has a consensus price target of $9.00, signalling upside risk potential of 65.75%. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $457.00 which suggests that it could grow by 35.94%. Given that CytomX Therapeutics, Inc. has higher upside potential than Alnylam Pharmaceuticals, Inc., analysts believe CytomX Therapeutics, Inc. is more attractive than Alnylam Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CTMXCytomX Therapeutics, Inc.5 2 0 ALNYAlnylam Pharmaceuticals, Inc.15 7 0 -
Is CTMX or ALNY More Risky?
CytomX Therapeutics, Inc. has a beta of 2.444, which suggesting that the stock is 144.417% more volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.350, suggesting its less volatile than the S&P 500 by 65.025%.
-
Which is a Better Dividend Stock CTMX or ALNY?
CytomX Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CytomX Therapeutics, Inc. pays -- of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CTMX or ALNY?
CytomX Therapeutics, Inc. quarterly revenues are $6M, which are smaller than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.1B. CytomX Therapeutics, Inc.'s net income of -$14.2M is lower than Alnylam Pharmaceuticals, Inc.'s net income of $186.4M. Notably, CytomX Therapeutics, Inc.'s price-to-earnings ratio is 12.98x while Alnylam Pharmaceuticals, Inc.'s PE ratio is 148.95x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CytomX Therapeutics, Inc. is 5.51x versus 12.08x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CTMXCytomX Therapeutics, Inc.5.51x 12.98x $6M -$14.2M ALNYAlnylam Pharmaceuticals, Inc.12.08x 148.95x $1.1B $186.4M
-
Which has Higher Returns CTMX or BMRN?
BioMarin Pharmaceutical, Inc. has a net margin of -238.62% compared to CytomX Therapeutics, Inc.'s net margin of -3.91%. CytomX Therapeutics, Inc.'s return on equity of 61.33% beat BioMarin Pharmaceutical, Inc.'s return on equity of 8.99%.
Company Gross Margin Earnings Per Share Invested Capital CTMXCytomX Therapeutics, Inc.97.75% -$0.09 $113M BMRNBioMarin Pharmaceutical, Inc.81.58% -$0.16 $6.7B -
What do Analysts Say About CTMX or BMRN?
CytomX Therapeutics, Inc. has a consensus price target of $9.00, signalling upside risk potential of 65.75%. On the other hand BioMarin Pharmaceutical, Inc. has an analysts' consensus of $88.87 which suggests that it could grow by 38.69%. Given that CytomX Therapeutics, Inc. has higher upside potential than BioMarin Pharmaceutical, Inc., analysts believe CytomX Therapeutics, Inc. is more attractive than BioMarin Pharmaceutical, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CTMXCytomX Therapeutics, Inc.5 2 0 BMRNBioMarin Pharmaceutical, Inc.14 6 0 -
Is CTMX or BMRN More Risky?
CytomX Therapeutics, Inc. has a beta of 2.444, which suggesting that the stock is 144.417% more volatile than S&P 500. In comparison BioMarin Pharmaceutical, Inc. has a beta of 0.256, suggesting its less volatile than the S&P 500 by 74.362%.
-
Which is a Better Dividend Stock CTMX or BMRN?
CytomX Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioMarin Pharmaceutical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CytomX Therapeutics, Inc. pays -- of its earnings as a dividend. BioMarin Pharmaceutical, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CTMX or BMRN?
CytomX Therapeutics, Inc. quarterly revenues are $6M, which are smaller than BioMarin Pharmaceutical, Inc. quarterly revenues of $786.8M. CytomX Therapeutics, Inc.'s net income of -$14.2M is higher than BioMarin Pharmaceutical, Inc.'s net income of -$30.7M. Notably, CytomX Therapeutics, Inc.'s price-to-earnings ratio is 12.98x while BioMarin Pharmaceutical, Inc.'s PE ratio is 24.01x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CytomX Therapeutics, Inc. is 5.51x versus 4.06x for BioMarin Pharmaceutical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CTMXCytomX Therapeutics, Inc.5.51x 12.98x $6M -$14.2M BMRNBioMarin Pharmaceutical, Inc.4.06x 24.01x $786.8M -$30.7M
-
Which has Higher Returns CTMX or RGNX?
REGENXBIO, Inc. has a net margin of -238.62% compared to CytomX Therapeutics, Inc.'s net margin of -208.32%. CytomX Therapeutics, Inc.'s return on equity of 61.33% beat REGENXBIO, Inc.'s return on equity of -73.5%.
Company Gross Margin Earnings Per Share Invested Capital CTMXCytomX Therapeutics, Inc.97.75% -$0.09 $113M RGNXREGENXBIO, Inc.67.68% -$1.20 $429.6M -
What do Analysts Say About CTMX or RGNX?
CytomX Therapeutics, Inc. has a consensus price target of $9.00, signalling upside risk potential of 65.75%. On the other hand REGENXBIO, Inc. has an analysts' consensus of $29.18 which suggests that it could grow by 258.5%. Given that REGENXBIO, Inc. has higher upside potential than CytomX Therapeutics, Inc., analysts believe REGENXBIO, Inc. is more attractive than CytomX Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CTMXCytomX Therapeutics, Inc.5 2 0 RGNXREGENXBIO, Inc.6 1 0 -
Is CTMX or RGNX More Risky?
CytomX Therapeutics, Inc. has a beta of 2.444, which suggesting that the stock is 144.417% more volatile than S&P 500. In comparison REGENXBIO, Inc. has a beta of 1.052, suggesting its more volatile than the S&P 500 by 5.23%.
-
Which is a Better Dividend Stock CTMX or RGNX?
CytomX Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. REGENXBIO, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CytomX Therapeutics, Inc. pays -- of its earnings as a dividend. REGENXBIO, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CTMX or RGNX?
CytomX Therapeutics, Inc. quarterly revenues are $6M, which are smaller than REGENXBIO, Inc. quarterly revenues of $29.7M. CytomX Therapeutics, Inc.'s net income of -$14.2M is higher than REGENXBIO, Inc.'s net income of -$61.9M. Notably, CytomX Therapeutics, Inc.'s price-to-earnings ratio is 12.98x while REGENXBIO, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CytomX Therapeutics, Inc. is 5.51x versus 2.58x for REGENXBIO, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CTMXCytomX Therapeutics, Inc.5.51x 12.98x $6M -$14.2M RGNXREGENXBIO, Inc.2.58x -- $29.7M -$61.9M
-
Which has Higher Returns CTMX or SVRA?
Savara, Inc. has a net margin of -238.62% compared to CytomX Therapeutics, Inc.'s net margin of --. CytomX Therapeutics, Inc.'s return on equity of 61.33% beat Savara, Inc.'s return on equity of -78.83%.
Company Gross Margin Earnings Per Share Invested Capital CTMXCytomX Therapeutics, Inc.97.75% -$0.09 $113M SVRASavara, Inc.-- -$0.14 $124.2M -
What do Analysts Say About CTMX or SVRA?
CytomX Therapeutics, Inc. has a consensus price target of $9.00, signalling upside risk potential of 65.75%. On the other hand Savara, Inc. has an analysts' consensus of $10.81 which suggests that it could grow by 95.52%. Given that Savara, Inc. has higher upside potential than CytomX Therapeutics, Inc., analysts believe Savara, Inc. is more attractive than CytomX Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CTMXCytomX Therapeutics, Inc.5 2 0 SVRASavara, Inc.6 0 0 -
Is CTMX or SVRA More Risky?
CytomX Therapeutics, Inc. has a beta of 2.444, which suggesting that the stock is 144.417% more volatile than S&P 500. In comparison Savara, Inc. has a beta of 0.336, suggesting its less volatile than the S&P 500 by 66.415%.
-
Which is a Better Dividend Stock CTMX or SVRA?
CytomX Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Savara, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CytomX Therapeutics, Inc. pays -- of its earnings as a dividend. Savara, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CTMX or SVRA?
CytomX Therapeutics, Inc. quarterly revenues are $6M, which are larger than Savara, Inc. quarterly revenues of --. CytomX Therapeutics, Inc.'s net income of -$14.2M is higher than Savara, Inc.'s net income of -$29.6M. Notably, CytomX Therapeutics, Inc.'s price-to-earnings ratio is 12.98x while Savara, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CytomX Therapeutics, Inc. is 5.51x versus -- for Savara, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CTMXCytomX Therapeutics, Inc.5.51x 12.98x $6M -$14.2M SVRASavara, Inc.-- -- -- -$29.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 29x
Alerts
Buy
77
RNG alert for Feb 21
RingCentral, Inc. [RNG] is up 34.37% over the past day.
Sell
9
FROG alert for Feb 21
JFrog Ltd. [FROG] is down 24.98% over the past day.
Buy
72
SNSE alert for Feb 21
Sensei Biotherapeutics, Inc. [SNSE] is up 23.81% over the past day.
